• linkedin
  • Increase Font
  • Sharebar

    Testosterone shows benefit against advanced PCa

    An advanced prostate cancer treatment protocol incorporating testosterone shows promise for treating the disease and reversing resistance to androgen deprivation therapy.

    RELATED: RT/hormone combo cuts PCa mortality in older men

    In a small study, published online in Science Translational Medicine (Jan. 7, 2015), researchers tested an approach based on the idea that if prostate cancer cells were flooded with testosterone, the cells might be killed by the hormone shock. The cells also might react by making fewer receptors, which may make the prostate tumor cells vulnerable once more to ADT.

    For the study, Samuel Denmeade, MD, and colleagues at Johns Hopkins University, Baltimore, enrolled 16 men who had been receiving testosterone-lowering treatment for metastatic prostate cancer at Johns Hopkins. All had been treated previously with at least one type of ADT and had rising levels of PSA and radiographic evidence their cancers were becoming resistant.

    The men were given three 28-day cycles of an intramuscular injection of testosterone and 2 weeks of etoposide (Etopophos). Men who showed decreases in PSA levels after three cycles were continued on testosterone injections alone.

    Of the 16 patients, two did not complete the study. One died of pneumonia and sepsis due to the etoposide, and the other experienced prolonged erection, a side effect of the testosterone.

    Of the remaining 14 patients, seven experienced a decline in their PSA levels of between 30% and 99%. The other seven men showed no decrease in PSA.

    In addition, four of the seven men who experienced a PSA drop stayed on testosterone therapy for 12 to 24 months with continued low PSA levels. Of 10 men whose metastatic cancers could be measured with imaging scans, five experienced tumor shrinkage by more than half, including one man whose cancer completely disappeared.

    Next: Potential to reverse resistance to T-blocking drugs

    More on Prostate Cancer

    Genomic test predicts rapid mets in men post-RP

    Prostate Bx: Urologists may be getting more selective

    Immunotherapy will define new era of GU cancer care

    Benjamin P. Saylor
    Saylor is content managing editor for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results